Progranulin variability has no major role in Parkinson disease genetic etiology

K. Nuytemans, P. Pals, K. Sleegers, S. Engelborghs, E. Corsmit, K. Peeters, B. Pickut, M. Mattheijssens, P. Cras, P. P. De Deyn, J. Theuns, C. Van Broeckhoven

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


BACKGROUND: Different loss-of-function mutations were identified underlying PGRN haploinsufficiency in patients with frontotemporal lobar degeneration. PGRN mutations were also identified in other neurodegenerative brain diseases such as amyotrophic lateral sclerosis and Alzheimer disease, though their biologic contribution to these diseases remains elusive. Because of its apparent role in neuronal survival, we argued that PGRN might also contribute to Parkinson disease (PD) pathogenesis. METHODS: We screened PGRN exons for mutations in 255 patients with PD and 459 control individuals by direct genomic sequencing. Genetic association of PGRN with risk for PD was assessed using single nucleotide polymorphisms (SNPs) across the gene. RESULTS: In patients we identified four missense mutations of which p.Asp33Glu and p.Arg514Met were absent in control individuals. Single SNP and haplotype analyses did not detect significant associations with PD. CONCLUSIONS: Our results do not support a major role for PGRN in the genetic etiology of Parkinson disease (PD). At this stage and in the absence of functional data, it remains unclear whether p.Asp33Glu and p.Arg514Met are biologically relevant to PD pathogenesis in the mutation carriers.

Original languageEnglish (US)
Pages (from-to)1147-1151
Number of pages5
Issue number15
StatePublished - Oct 7 2008
Externally publishedYes

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Progranulin variability has no major role in Parkinson disease genetic etiology'. Together they form a unique fingerprint.

Cite this